| Project/Area Number |
25861133
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kobe Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 放射線 / がん / がん内用放射線療法 / NQO1 / がん内用放射線治療薬剤 |
|---|
| Outline of Final Research Achievements |
NAD(P)H: quinone oxidoreductase 1 (NQO1) is highly expressed in many human solid cancers. Because NQO1 can be induced immediately after exposure to ionizing radiation, we aimed to develop an NQO1-targeted radioiodinated agent to establish a novel internal radiation therapy that amplifies the therapeutic effects when combined with external radiation therapy. The metabolic stability of NQO1-targeted radioiodinated compounds previously reported was low because of the electron withdrawing effect of iodine atom. Then, we designed and synthesis of a new NQO1-targeted radioiodinated derivative having methoxy group as a electron donating group. As a result, radioiodinated derivative exhibited goood metabolic stabilty in NQO1-expressing HT-29 cell lysates.
|
